News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation

Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% label

AR-13324-CS205 Clinical Pilot Study Topline Results

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
Conference Call and Webcast Today, May 7 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--May 7, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M
DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Matches ASCRS Foundation Fund Raising to Provide Sight-Saving Surgery for the World’s Neediest Patients
-- Donations to Foundation programs by attendees of the 2019 ASCRS-ASOA Annual Meeting will be matched up to $30,000 --   SAN DIEGO, CALIFORNIA – May 2, 2019 — Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization
View HTML
Toggle Summary Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and Increase in Rhopressa® Medicare Part D Coverage to Approximately 75% of Lives
DURHAM, N.C. --(BUSINESS WIRE)--May 1, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
TOP